June 2025 - Page 3 of 14

Release – InPlay Oil Corp. Announces Annual Meeting Voting Results for Election of Directors

Posted on June 25, 2025June 26, 2025 by aweinsoff@channelchek.com

Jun 25, 2025, 21:34 ET

CALGARY, AB , June 25, 2025 /CNW/ – InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company”) announced today the voting results for the election of directors at its annual meeting of shareholders held on June 25, 2025 (the “Meeting”). The following eight nominees were elected as directors of InPlay to serve until the next annual meeting of shareholders or until their successors are elected or appointed, with common shares represented at the Meeting voting in favour of individual nominees as follows:

Director	Percentage Approval	Percentage Withheld
Douglas Bartole	99.73 %	0.27 %
Regan Davis	99.64 %	0.36 %
Joan Dunne	94.73 %	5.27 %
Craig Golinowski	99.70 %	0.30 %
Stephen Loukas	92.94 %	7.06 %
Stephen Nikiforuk	94.71 %	5.29 %
Peter Scott	99.86 %	0.14 %
Dale Shwed	99.66 %	0.34 %

In addition, all other resolutions presented at the Meeting were approved by InPlay’s shareholders, including the appointment of PriceWaterhouseCoopers LLP as auditors, InPlay’s restricted and performance award incentive plan and the settlement from treasury of incentive awards previously granted thereunder and the approval the unallocated options issuable under InPlay’s share option plan. For complete voting results, please see our Report of Voting Results which is available through SEDAR+ at www.sedarplus.ca.

InPlay is based in Calgary, Alberta and the common shares of InPlay are traded on the Toronto Stock Exchange under the trading symbol “IPO”. For further information about InPlay, please visit our website at www.inplayoil.com.

SOURCE InPlay Oil Corp.

For further information please contact: Doug Bartole, President and Chief Executive Officer InPlay Oil Corp., Telephone: (587) 955-0632; Darren Dittmer, Chief Financial Officer InPlay Oil Corp., Telephone: (587) 955-0634

Release – Bit Digital Inc. Announces Strategic Shift to Ethereum Treasury and Staking Operations

Posted on June 25, 2025June 26, 2025 by aweinsoff@channelchek.com

Research News and Market Data on BTBT

NEW YORK, June 25, 2025 /PRNewswire/ — Bit Digital, Inc. (Nasdaq: BTBT) (“Bit Digital” or the “Company”), today announced that it has initiated a strategic transition to become a pure play Ethereum (“ETH”) staking and treasury company. The Company began accumulating ETH and operating staking infrastructure in 2022 and has steadily increased its holdings since that time.

As of March 31, 2025, the Company held 24,434.2 ETH and 417.6 BTC, valued at approximately $44.6 million and $34.5 million, respectively, as of that date. Bit Digital intends to convert its BTC holdings into ETH over time.

In connection with the transition, the Company has commenced a strategic alternatives process for its bitcoin mining operations that is expected to result in their sale or wind-down, with any net proceeds to be re-deployed into ETH.

About Bit Digital

Bit Digital is a publicly traded digital asset platform focused on Ethereum-native treasury and staking strategies. For additional information, please contact ir@bit-digital.com or follow us on LinkedIn or X.

Safe Harbor Statement

This press release may contain certain “forward-looking statements” relating to the business of Bit Digital, Inc., and its subsidiary companies. All statements, other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Release – Kratos Defense & Security Solutions, Inc. Announces Proposed Public Offering Of Common Stock

Posted on June 25, 2025June 26, 2025 by aweinsoff@channelchek.com

Research News and Market Data on KTOS

June 25, 2025 at 4:00 PM EDT

PDF Version

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (“Kratos”) (NASDAQ: KTOS), a Technology Company in the Defense, National Security and Commercial Markets, today announced that it intends to offer for sale $500,000,000 of shares of its common stock in an underwritten offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”). The underwriters will have a 30-day option to purchase up to an additional $75,000,000 of shares of common stock from Kratos. All of the shares in the offering are to be sold by Kratos. The proposed offering is subject to market and other conditions.

Kratos expects to use the net proceeds of the offering to (i) fund investments and capital expenditures to scale and successfully execute on large, mission critical National Security priorities related to existing programs, recent program awards and significant high-probability pipeline opportunities; (ii) to finance important customer and program targeted acquisitions; (iii) and for general corporate purposes, including pay-down of debt and to pay fees and expenses in connection with the offering.

Baird, RBC Capital Markets, Truist Securities, and Raymond James are acting as joint book-running managers for the offering.

The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-277222) that was previously filed by Kratos with the SEC and automatically became effective upon filing on February 21, 2024. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

The offering will be made only by means of a prospectus supplement and the accompanying prospectus. The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, from Robert W. Baird & Co. Incorporated, 777 E. Wisconsin Avenue, Milwaukee, Wisconsin 53202, by telephone at (800) 792-2473, or by email at syndicate@rwbaird.com, RBC Capital Markets, LLC, 200 Vesey Street, New York, New York 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com, Truist Securities, Inc., 3333 Peachtree Road NE, 9^th Floor, Atlanta, Georgia 30326, by telephone at (800) 685-4786, or by email at TruistSecurities.prospectus@Truist.com, and Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, FL 33716, by telephone at (800) 248-8863, or by email at prospectus@raymondjames.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at www.sec.gov.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to a variety of matters, including, without limitation, Kratos’ expectations regarding the sale of shares of its common stock in the proposed public offering, use of the expected proceeds from the proposed public offering and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements including, but not limited to: risks and uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed public offering, as well as general economic factors. There can be no assurance that Kratos will be able to complete the proposed public offering on the anticipated terms, or at all. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024 and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Burghoff
claire.burghoff@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

Rubrik to Acquire AI Startup Predibase in Strategic Expansion Push

Posted on June 25, 2025June 25, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Rubrik is acquiring AI startup Predibase for over $100 million to expand into enterprise AI infrastructure.
– Predibase’s platform allows businesses to customize and deploy AI models using data from third-party sources.
– The acquisition aligns with Rubrik’s strategy to evolve into a multi-product enterprise platform focused on security and AI innovation.

Rubrik, the data security and management company, is set to acquire artificial intelligence startup Predibase in a move that deepens its presence in the fast-growing AI infrastructure market. The acquisition, valued at over $100 million according to a source familiar with the terms, marks a significant step in Rubrik’s efforts to broaden its capabilities beyond data backup and cyber resilience.

Predibase, founded in 2021, specializes in tools that help organizations efficiently deploy custom AI models using their own data. The San Francisco-based startup has attracted attention for its developer-focused platform that integrates with a wide range of third-party data systems. By enabling customization and deployment of large language models (LLMs), Predibase aims to help businesses move beyond generic AI tools and build solutions tailored to their internal data needs.

Rubrik, which went public in 2024 and has seen robust revenue growth since its IPO, views the deal as an opportunity to evolve into a multi-product enterprise software provider. The company has already established itself as a key player in data protection and ransomware recovery, boasting more than $1 billion in annualized recurring revenue. The integration of Predibase’s AI model deployment tools adds a new layer to Rubrik’s offerings—one that taps into the increasing demand for AI-powered automation across enterprises.

With this acquisition, Rubrik aims to give customers the ability to build secure, cost-effective AI agents that can reason over large datasets housed within both Rubrik’s ecosystem and external cloud platforms. These include major cloud data players such as Amazon Web Services, Google Cloud, Snowflake, and Databricks, with whom Predibase already integrates.

The Predibase platform will continue to operate independently after the acquisition closes, preserving its existing customer relationships and developer-centric approach. Predibase’s technology will also be enhanced by Rubrik’s Annapurna platform, which enables secure aggregation of data from multiple sources. Together, the two platforms are expected to provide businesses with an end-to-end stack for building and deploying AI models grounded in private enterprise data.

Predibase’s team, including co-founders who previously worked on AI infrastructure at Uber, brings technical depth and credibility to Rubrik’s expanding AI strategy. Their work at Uber on machine learning platforms laid the groundwork for scalable AI services, and they bring similar ambitions to their new parent company.

For Rubrik, the acquisition underscores a broader ambition to become a long-term platform player in the enterprise technology space. As more businesses look to harness generative AI for insights and automation, the demand for tools that enable secure, high-performance model training and deployment is growing rapidly. With Predibase now in its fold, Rubrik is positioning itself to be at the center of this next wave of enterprise AI adoption.

Release – GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection

Posted on June 25, 2025June 25, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Patent Supports Multi‑Antigenic VLP-MVA Vaccine Design for Products Used Against Endemic and Emerging Infectious Diseases

ATLANTA, GA, June 25, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,329,808, from patent application No.18,394,580, titled “Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria.”

The patent covers compositions comprising GeoVax’s recombinant Modified Vaccinia Ankara (MVA) viral vector expressing immunogenic proteins from Plasmodium falciparum (the causative agent of malaria). The novel construct supports expression of virus-like particles (VLPs) assembled from P. falciparum circumsporozoite protein (CSP) or gametocyte surface protein Pfs230 fused to a Marburg virus glycoprotein transmembrane domain, together with the Marburg VP40 matrix protein. The expressed proteins are assembled in vivo as VLPs, which is an antigen presentation design used to enhance vaccine potency and induce both humoral and T-cell responses.

David Dodd, GeoVax President and CEO, commented, “This new patent further demonstrates our commitment to advancing critically important vaccines that address both globally persistent and emerging high-consequence pathogens. The vaccine construct exemplifies our multi-antigenic platform strategy that is critical to pandemic preparedness and global health security. While our clinical-stage programs remain our immediate focus, protecting our innovation pipeline through issued patents supports long-term value creation and future public health impact.”

GeoVax’s intellectual property estate now encompasses over 135 granted or pending patent applications across 23 distinct patent families, reinforcing the company’s strategic position across oncology, infectious diseases, and biodefense platforms. This broad portfolio includes strong protection for its Gedeptin® oncolytic cancer therapy, recently expanded to cover synergistic combinations with radiation, and multiple MVA‑based vaccine constructs targeting SARS‑CoV‑2, Mpox/smallpox, Zika, Ebola, Sudan, and Marburg viruses.

Malaria remains a persistent global health threat, causing over 600,000 deaths yearly, primarily in sub-Saharan Africa. The use of GeoVax’s versatile MVA-based platform offers the potential for inducing durable immunity against both such latent and emerging pathogens.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

info@geovax.com

678-384-7220

Investor Relations Contact:

geovax@precisionaq.com

212-698-8696

Media Contact:

Jessica Starman

media@geovax.com

AZZ Inc. to Review First Quarter Fiscal Year 2026 Financial Results on Thursday, July 10, 2025

Posted on June 25, 2025June 25, 2025 by aweinsoff@channelchek.com

Research News and Market Data on AZZ

FORT WORTH, Texas, June 25, 2025 /PRNewswire/ — AZZ Inc. (NYSE: AZZ), the leading independent provider of hot-dip galvanizing and coil coating solutions, today announced it will conduct a conference call to review the financial results for the first quarter fiscal year 2026 at 11:00 a.m. ET on Thursday, July 10, 2025. The Company will issue a press release reporting first quarter financial results after the market closes on July 9, 2025.

Conference Call Details
Interested parties can access the conference call by dialing (844) 855-9499 or (412) 317-5497 (international). A webcast of the call will be available on the Company’s Investor Relations page at http://www.azz.com/investor-relations.

A replay of the call will be available at (877) 344-7529 or (412) 317-0088 (international), replay access code: 2234808, through July 17, 2025, or by visiting http://www.azz.com/investor-relations for the next 12 months.

About AZZ Inc.
AZZ Inc. is the leading independent provider of hot-dip galvanizing and coil coating solutions to a broad range of end-markets. Collectively, our business segments provide sustainable, unmatched metal coating solutions that enhance the longevity and appearance of buildings, products and infrastructure that are essential to everyday life. For more information, please refer to www.azz.com.

Safe Harbor Statement
Certain statements herein about our expectations of future events or results constitute forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by terminology such as “may,” “could,” “should,” “expects,” “plans,” “will,” “might,” “would,” “projects,” “currently,” “intends,” “outlook,” “forecasts,” “targets,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. Such forward-looking statements are based on currently available competitive, financial, and economic data and management’s views and assumptions regarding future events. Such forward-looking statements are inherently uncertain, and investors must recognize that actual results may differ from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date they are made and are subject to risks that could cause them to differ materially from actual results. Certain factors could affect the outcome of the matters described herein. This press release may contain forward-looking statements that involve risks and uncertainties including, but not limited to, changes in customer demand for our manufactured solutions, including demand by the construction markets, the industrial markets, and the metal coatings markets. We could also experience additional increases in labor costs, components and raw materials including zinc and natural gas, which are used in our hot-dip galvanizing process, paint used in our coil coating process; supply-chain vendor delays; customer requested delays of our manufactured solutions; delays in additional acquisition opportunities; an increase in our debt leverage and/or interest rates on our debt, of which a significant portion is tied to variable interest rates; availability of experienced management and employees to implement AZZ’s growth strategy; a downturn in market conditions in any industry relating to the manufactured solutions that we provide; economic volatility, including a prolonged economic downturn or macroeconomic conditions such as inflation or changes in the political stability in the United States and other foreign markets in which we operate; tariffs; acts of war or terrorism inside the United States or abroad; and other changes in economic and financial conditions. AZZ has provided additional information regarding risks associated with the business, including in Part I, Item 1A. Risk Factors, in AZZ’s Annual Report on Form 10-K for the fiscal year ended February 28, 2025, and other filings with the SEC, available for viewing on AZZ’s website at www.azz.com and on the SEC’s website at www.sec.gov.

You are urged to consider these factors carefully when evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. These statements are based on information as of the date hereof and AZZ assumes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contact:
David Nark, Senior Vice President of Marketing, Communications, and Investor Relations
AZZ Inc.
(817) 810-0095
www.azz.com

Investor Contact:
Sandy Martin or Phillip Kupper
Three Part Advisors
(214) 616-2207 or (817) 368-2556
www.threepa.com

SOURCE AZZ, Inc.

Comstock (LODE) – Strategic Partnership with Virtus Renewables

Posted on June 25, 2025June 25, 2025 by slightbourne@noblecapitalmarkets.com

Wednesday, June 25, 2025

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strategic partnership with Virtus. Comstock Metals forged a strategic partnership with Virtus Renewables Service Group Inc. Comstock and Virtus will jointly develop and deliver comprehensive recycling, decommissioning, and logistics solutions designed to suit the specific needs of the renewable energy markets. The partnership enables a systemwide service offering with expanded industry reach to offer environmentally conscious solutions for renewable energy clients across the United States.

Mutual benefits. Virtus offers a comprehensive suite of operations, project management, and maintenance services for solar and battery storage projects. Combining Virtus’s end-to-end renewable energy service expertise with Comstock’s industry-leading, zero-landfill solution enhances its ability to serve the renewable energy market and benefit from a full lifecycle certification process that adheres to the highest standards of sustainability, reliability, and service. Comstock is the first solar panel recycling company in North America to be certified by Sustainable Electronics Recycling International (SERI) to the R2v3/RIOS Responsible Recycling Standard.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Consumer Confidence Slips as Tariff Worries and Price Pressures Resurface

Posted on June 25, 2025June 25, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Consumer confidence fell unexpectedly in June, driven by concerns over tariffs and inflation.
– Perceptions of the labor market have softened, with fewer respondents viewing jobs as readily available.
– Despite rising geopolitical tensions, trade policy and high prices remain the primary concerns for American consumers.

Consumer confidence took an unexpected step back in June, reflecting growing anxieties around tariffs and persistent inflation that continue to shape household sentiment. Despite a brief upswing the previous month, optimism around the economy and job market has moderated as Americans grow more cautious about future conditions.

The Conference Board’s Consumer Confidence Index dipped to 93 in June, a notable decline from 98.4 in May and below economists’ projections. The Expectations Index, which measures consumers’ outlook for income, business, and labor conditions over the next six months, dropped to 69 from 73.6. The sharp decline follows what had been the largest one-month surge in sentiment since the financial crisis recovery in 2009.

Tariffs remained on top of consumers’ minds and were frequently associated with concerns about their negative impacts on the economy and prices. Inflation and high prices were another important concern cited by consumers in June.

Although the administration has delayed several rounds of tariffs in recent weeks, the effective U.S. tariff rate remains significantly elevated. According to estimates from the Yale Budget Lab, the current rate stands at approximately 14.7%—the highest since the Great Depression era in 1938. This has raised the cost of imported goods and weighed on consumer sentiment, especially for lower- and middle-income households who are more sensitive to rising everyday expenses.

Interestingly, geopolitical events, including renewed conflict in the Middle East, were not cited as major factors in consumer sentiment. The survey cutoff occurred amid increasing global tensions, but Guichard noted that topics like international conflict and social unrest “remained much lower on the list of topics affecting consumers’ views.”

Labor market perceptions also softened in June. The share of consumers who said jobs are “plentiful” declined to 29.2%, down from 31.1% the month before. At the same time, 18.1% of respondents said jobs were “hard to get,” nearly unchanged from May. The gap between these two numbers—known as the labor market differential—narrowed to 11.1 percentage points, its lowest level since early 2021 when the economy was emerging from pandemic-era shutdowns.

The cooling in labor sentiment mirrors recent trends in government data. Job openings have declined from earlier in the year, and unemployment claims have risen, suggesting some softening in what had been a resilient job market.

While the recent pullback in confidence does not necessarily signal a recession, it highlights the fragility of sentiment in the face of policy uncertainty and inflationary pressure. As the Federal Reserve continues to weigh interest rate decisions and the White House balances trade policy with economic growth, consumer perceptions will remain a key bellwether for the broader economic outlook.

Release – GeoVax Comments on FDA Approval of Keytruda® in Head and Neck Cancer, Underscoring Potential for Gedeptin® Combination Therapy

Posted on June 24, 2025June 24, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Supports Advancement of GeoVax’s Phase 2 Gedeptin® Trial in Recurrent Head and Neck Cancer

ATLANTA, GA, June 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today commented on the U.S. Food and Drug Administration’s recent approval of Keytruda® (pembrolizumab) for use in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) tumors expressing PD-L1 as determined by an FDA approved test. This regulatory milestone marks a significant advancement in the curative-intent treatment landscape for head and neck cancer and affirms the therapeutic strategy underlying GeoVax’s Gedeptin® development program.

An editorial by Rosenberg and Vokes in New England Journal of Medicine (NEJM) noted that the study forming the basis of FDA’s approval represents the first demonstration of benefit for PD-1 inhibition in the curative setting for HNSCC, with implications for evolving neoadjuvant immunotherapy paradigms.

GeoVax is planning to initiate a Phase 2 clinical trial of Gedeptin® in combination with a checkpoint inhibitor, such as pembrolizumab, in patients with locally advanced HNSCC scheduled for curative-intent surgery. The trial aims to improve tumor clearance and reduce relapse by combining the immune-priming effect of Gedeptin’s targeted cytotoxicity with the systemic immune activation of checkpoint inhibition.

The Phase 2 study, expected to launch in 2026, will evaluate pathologic response, recurrence rates, and biomarker-defined immunologic changes when Gedeptin is used as neoadjuvant therapy with checkpoint inhibitors. Importantly, the NEJM editorial emphasized the need to optimize patient selection and treatment duration in the immunotherapy era, aligning with GeoVax’s biomarker-driven approach.

“The NEJM publication and FDA approval of Keytruda in resectable HNSCC signals a new era in curative-intent cancer therapy,” said David Dodd, Chairman and CEO of GeoVax. “By combining Gedeptin therapy with pembrolizumab, we aim to enhance local tumor eradication while unlocking systemic anti-tumor immunity, potentially reducing both local and distant recurrence.”

“We believe Gedeptin’s tumor-targeted cytotoxicity can enhance immunotherapy efficacy, particularly in the perioperative window where anti-tumor immunity can be primed,” added Dr. Kelly McKee, GeoVax’s Chief Medical Officer. “We are excited to embark on the next phase of Gedeptin development as we attempt to build on the important advances being made in this disease”.

For more information about the KEYNOTE-689 study, see the June 18, 2025 publication in the New England Journal of Medicine.

About Gedeptin

Gedeptin® is a gene-directed enzyme prodrug therapy (GDEPT) delivered intratumorally via an adenoviral vector encoding purine nucleoside phosphorylase (PNP). Upon systemic administration of fludarabine, the enzyme catalyzes the generation of a cytotoxic agent selectively within the tumor microenvironment. This mechanism provides dual cytotoxicity and immune modulation with minimal systemic exposure.

Gedeptin has been granted Orphan Drug Designation by the FDA for the treatment of oral and pharyngeal cancers and is protected by a growing intellectual property portfolio. GeoVax’s ongoing innovation in immune-sensitizing therapies supports a broader strategy to complement checkpoint inhibitors and overcome tumor immune resistance across solid tumor types.

About GeoVax

Forward-Looking Statements

Company Contact:

info@geovax.com

678-384-7220

Investor Relations Contact:

geovax@precisionaq.com

212-698-8696

Media Contact:

Jessica Starman

media@geovax.com

Release – ARK Demonstrates Robust June Momentum as Snail Games Celebrates 10-Year Anniversary and Prepares for Aquatica DLC Launch

Posted on June 24, 2025June 24, 2025 by aweinsoff@channelchek.com

Research News and Market Data on SNAL

June 24, 2025 at 8:30 AM EDT

PDF Version

ARK: Survival Evolved sees over 3,000% sales lift in June

Snail leverages box office and music partnerships to promote ARK: Aquatica

CULVER CITY, Calif., June 24, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, celebrates the ARK franchise’s 10-year anniversary with strong June 2025 sales momentum across ARK: Survival Evolved (“ASE”) and it launches targeted marketing strategy to drive engagement for the upcoming ARK: Aquatica DLC.

Following the recent Snail Steam Publisher Sale, ARK: Survival Evolved saw a sharp resurgence in player engagement and sales, with over 3.8x total units sold and average daily sales increasing by 3,022% during Snail’s Steam Publisher Sale compared to prior months in 2025. Concurrent players peaked at 65,885, underscoring the franchise’s enduring global community engagement even a decade after its original debut. These results reflect not only the franchise’s lasting popularity and staying power, but also Snail Games’ ongoing commitment to sustaining player engagement through consistent content updates and releases.

Snail Games co-CEO Tony Tian commented: “As we celebrate 10 years of ARK and set the stage for ARK: Aquatica’s release, we are embracing the intersection of gaming and entertainment to reach new fans wherever they are and drive long-term value for the franchise. The success of ASE continues to serve as a foundation for future growth, and with a highly engaged community and strong performance benchmarks, we expect ARK: Aquatica to capitalize on this momentum upon release.”

As part of a larger marketing and media strategy, Snail Games broadcasted an ARK: Aquatica ad during the pre-show of How to Train Your Dragon live action remake, which opened to approximately $83.7 million at the domestic box office. This high-visibility media placement underscores Snail’s commitment to positioning ARK at the intersection of gaming and mainstream entertainment. Further reinforcing this vision, Snail also launched the official Steam page for “On My Way,” a standalone track created in collaboration with Luminati Suns for the ARK: Aquatica DLC. The song represents a continued push to expand the franchise into adjacent entertainment verticals and broaden audience engagement.

In parallel with its efforts on ARK: Survival Evolved and its upcoming ARK: Aquatica DLC, Snail continues to expand the ARK universe. On mobile devices, ARK: Ultimate Mobile Edition introduced the Genesis Part 1 expansion, driving up first time downloads by 27.4% and DAU by 17.8% during launch week when compared to the week prior. Meanwhile, ARK: Survival Ascended added Ragnarok Ascended, resulting in ARK Survival Ascended’s highest Steam peak CCU and DAU in 2025. Lost Colony Expansion Pass, the first expansion map built exclusively for ARK: Survival Ascended and was also the number 1 pre-order on Playstation this weekend. These new and upcoming content launches further reinforce Snail’s commitment to ongoing franchise investment, platform-specific growth, and long-term player engagement across the ARK ecosystem.

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, Snail’s commitment to positioning ARK at the intersection of gaming and mainstream entertainment and reaching new fans wherever they are located in order to drive long-term value for the Company’s intellectual property. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company’s Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
SNAL@gateway-grp.com

Fed in No Rush: Powell Stands Firm as Trump Pushes for Rate Cuts

Posted on June 24, 2025June 24, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Fed Chair Jerome Powell signals patience on interest rates amid economic and geopolitical uncertainty.
– Rising political pressure, including sharp criticism from President Trump, has not swayed the Fed’s cautious approach.
– Internal divisions within the Fed highlight uncertainty over the timing and necessity of potential rate cuts.

Federal Reserve Chair Jerome Powell has reaffirmed the central bank’s cautious stance on interest rate policy, signaling that the Fed is in no rush to cut rates as it awaits greater clarity on the economic impact of rising tariffs and geopolitical uncertainty.

In testimony before lawmakers, Powell said the Federal Reserve is “well-positioned to wait” before adjusting monetary policy, citing the need for more data on how recent trade actions and inflation trends will evolve. His remarks come at a time of heightened pressure from the White House, with President Trump calling for sharp and immediate rate cuts, and some Fed officials themselves suggesting a more dovish pivot.

“Increases in tariffs are likely to push up prices and weigh on economic activity,” Powell told members of Congress. He emphasized the uncertainty surrounding how lasting these effects might be. “The inflationary impact could be transitory, but it could also prove more persistent. We simply don’t know yet.”

The Fed has held rates steady for multiple consecutive meetings, keeping its benchmark range between 4.25% and 4.5%, and has maintained a data-dependent approach as economic conditions shift. Powell reiterated that any future move—whether a rate cut or continued pause—will depend on evolving inflation data, labor market health, and broader global developments.

The conversation around monetary policy has grown increasingly politicized. President Trump has sharply criticized Powell and the Fed’s decision-making, calling for rates to be slashed significantly. In public statements and on social media, Trump has demanded rates between 1% and 2%, going so far as to insult Powell personally and muse about removing him from his post.

Despite these attacks, Powell stood firm. “We are focused on one thing: delivering a good economy for the benefit of the American people,” he said. “Anything else is a distraction.”

While Powell maintained a neutral tone, some members of the Fed’s policymaking committee have expressed more urgency. Governor Michelle Bowman recently argued for potential rate cuts in the near term, citing weaker consumer spending and softening labor trends. Others, including Cleveland Fed President Beth Hammack, have countered that the economy remains too strong to justify immediate easing.

The division is also evident in the Fed’s internal projections. A recent summary of economic projections revealed a split among officials: some anticipate two rate cuts this year, while others favor keeping rates unchanged for longer, especially amid risks of renewed inflation due to tariffs and potential oil price shocks.

International developments, including tensions in the Middle East and volatile energy markets, add another layer of complexity. Some analysts warn that a sustained rise in oil prices—driven by potential disruptions in the Strait of Hormuz—could reignite inflation pressures and delay any rate relief.

Despite the political noise and market speculation, Powell has made clear that the Fed’s course will be guided by economic fundamentals. With inflation moderating but not vanquished, and growth showing signs of deceleration, the central bank faces a delicate balancing act in the months ahead.

Release – MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

Posted on June 24, 2025June 24, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MAIA

June 24, 2025 8:15am EDT Download as PDF

Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA’s lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor.

As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (CST) in HCC and may participate in future investigator sponsored trials (IST).

“Drs. Pinato and Fulgenzi are scientific experts on inflammation as a pathogenic and prognostic mechanism in primary liver cancers. Together, their research has focused on improving the treatment of HCC, particularly with the use of anti-cancer immunotherapy,” said MAIA Chairman and CEO Vlad Vitoc, M.D. “They will bring a wealth of knowledge to our SAB, with specialized expertise that will inform our plans and preparations for our upcoming clinical program in HCC.

“By the end of this year, we expect to have all required approvals to begin enrolling patients in a HCC trial,” Dr. Vitoc added.

MAIA was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for ateganosine as a treatment for HCC in 2022. ODDs can provide up to seven years of market exclusivity.

Dr. David Pinato is a clinician scientist in the Department of Surgery and Cancer at Imperial College London and a consultant oncologist at Imperial College Healthcare NHS Trust. As Director of Developmental Cancer Therapeutics at Imperial College, he leads a translational research program focused on the early clinical implementation of novel experimental anticancer therapies with particular emphasis on anti-cancer immunotherapy.

Dr. Pinato’s research efforts in liver cancer have been recognized by the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). He has received awards by the British Society of Pharmacology and the Royal Society of Medicine, and fellowships by the European School of Oncology and Fulbright Program.

Dr. Pinato completed his core medical training across some of the busiest acute hospitals in London and was elected to the Royal College of Physicians (MRCP). His research has been published in leading journals in the field including the Journal of Clinical Oncology, Annals of Oncology, Hepatology and many others. Dr. Pinato lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for several peer-reviewed journals including The Lancet, Cancer Discovery, Hepatology and Journal of Hepatology.

Dr. Claudia Fulgenzi is a specialist in medical oncology at Imperial College London, with dedicated professional interest in the field of immune-oncology and gastro-intestinal cancers, particularly hepatic-biliary malignancies. Dr. Fulgenzi graduated in medicine from the University of Rome Tor Vergata and subsequently specialized in medical oncology at the University Campus Bio Medico of Rome, Italy. Her contributions to the field have been recognized with prestigious awards including the ASCO Merit Award, the Young Investigator award by the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology.

Dr. Fulgenzi is actively engaged in clinical practice in London, serving as an honorary consultant in oncology at Chelsea and Westminster Hospital and as a specialty doctor in the early phase clinical trial unit at Hammersmith Hospital. In these capacities, she conducts clinical and translational research, contributes to clinical trial design, and provides expert medical guidance to cancer patients.

Hepatocellular carcinoma is the most frequently occurring primary liver tumor representing approximately 90% of all liver cancers. HCC currently ranks 5th by incidence and 3rd by mortality on a global scale.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250624640390/en/

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released June 24, 2025

QuoteMedia Inc. (QMCI) – Raising Price Target On Favorable Outlook

Posted on June 24, 2025June 24, 2025 by slightbourne@noblecapitalmarkets.com

Tuesday, June 24, 2025

QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies. The Company licenses interactive stock research tools such as streaming real-time quotes, market research, news, charting, option chains, filings, corporate financials, insider reports, market indices, portfolio management systems, and data feeds. QuoteMedia provides industry leading market data solutions and financial services for companies such as the Nasdaq Stock Exchange, TMX Group (TSX Stock Exchange), Canadian Securities Exchange (CSE), London Stock Exchange Group, FIS, U.S. Bank, Broadridge Financial Systems, JPMorgan Chase, CI Financial, Canaccord Genuity Corp., Hilltop Securities, HD Vest, Stockhouse, Zacks Investment Research, General Electric, Boeing, Bombardier, Telus International, Business Wire, PR Newswire, FolioFN, Regal Securities, ChoiceTrade, Cetera Financial Group, Dynamic Trend, Inc., Qtrade Financial, CNW Group, IA Private Wealth, Ally Invest, Inc., Suncor, Virtual Brokers, Leede Jones Gable, Firstrade Securities, Charles Schwab, First Financial, Cirano, Equisolve, Stock-Trak, Mergent, Cision, Day Trade Dash and others. Quotestream®, QModTM and Quotestream ConnectTM are trademarks of QuoteMedia. For more information, please visit www.quotemedia.com.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q1 Results. The company reported solid Q1 results, with revenue growing 3% over the prior year period to $4.8 million, marking the highest quarterly revenue in the company’s history. Adj. EBITDA of $0.4 million in Q1 was moderately lower than our estimate of $0.5 million estimate. We believe its business pipeline appears to be improving and should gain momentum throughout the year and into 2026.

Capitalizing less development costs. Notably, the company capitalized less development costs in Q1 than in prior quarters, leading to more development costs expensed in Q1. While this impacted Q1, we believe that margins should improve as the company begins to recognize the revenue from the new business “wins” in future quarters. Furthermore, the company will be expensing development costs at a similar rate to Q1 moving forward.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).